603087 Gan & Lee Pharmaceuticals.
- 48.52
- +0.03+0.06%
Gan & Lee Pharmaceuticals. News
Gan & Lee Pharmaceuticals Gets Mexico's Drug Registration Approval for Insulin Glargine Injection
Gan & Lee Pharmaceuticals (SHA:603087) secured drug registration approval for its insulin glargine injection, BAGILIN, in Mexico. The long-acting insulin analog product is injected once a day and can
Ganli Pharmaceutical (603087.SH): Glycine insulin injection (pre-filled pen) obtained Mexican drug registration approval
Gelonghui, May 23 | Ganli Pharmaceutical (603087.SH) announced that it has received registration approval (approval number: 066M2024SSA) for insulin glargine injections (pre-filled pens) issued by COFEPRIS (Comisión FederalParalaProtección ContrariesGossanitario) from the Mexican Federal Health Risk Protection Agency. Insulin glycine injection is a long-acting insulin analog product, also known as a basic insulin analog. It is injected once a day, and the effect lasts for 24 hours after the injection is effective.
Ganli Pharmaceutical (603087.SH): Grant 7.04 million restricted shares to incentive recipients
Gelonghui, May 15, 丨 Ganli Pharmaceutical (603087.SH) announced that the company decided to grant 7.04 million restricted shares to 87 incentive recipients who met the grant conditions at a grant price of RMB 19.79 yuan/share on May 15, 2024.
We Think That There Are Issues Underlying Gan & Lee Pharmaceuticals' (SHSE:603087) Earnings
Gan & Lee Pharmaceuticals.'s (SHSE:603087) robust earnings report didn't manage to move the market for its stock. We did some digging, and we found some concerning factors in the details. SHSE:603
Earnings Miss: Gan & Lee Pharmaceuticals. Missed EPS By 30% And Analysts Are Revising Their Forecasts
As you might know, Gan & Lee Pharmaceuticals. (SHSE:603087) last week released its latest quarterly, and things did not turn out so great for shareholders. Unfortunately, Gan & Lee Pharmaceutical
2024 Financial Report | Insulin Low Price Competition, Gan Li Pharmaceutical's Gains and Losses
Go out to sea
Ganli Pharmaceutical (603087.SH) reported 2023 results, with net profit of 340 million yuan, turning a year-on-year loss into a profit
Ganli Pharmaceutical (603087.SH) released its 2023 annual report, achieving revenue of 2,608 billion yuan,...
Guojin Securities: Continued increase in domestic insulin share is expected to drive continued growth in performance
Since May 2022, national special insulin collection has been launched in various provinces and cities. While the price of insulin products has declined, the domestic substitution process has greatly accelerated.
Ganli Pharmaceutical (603087.SH) completed its first phase I clinical trial of GZR18 tablets in China
Ganli Pharmaceutical (603087.SH) announced that Gan Li Pharmaceutical Shandong Co., Ltd., a wholly-owned subsidiary of the company, independently developed G...
Minghua Innovation, a shareholder of Ganli Pharmaceutical (603087.SH), reduced its shareholding by 1.81%
Ganli Pharmaceutical (603087.SH) issued an announcement. Recently, the company received a written notice from shareholder Minghua Innovation. It...
Ganli Pharmaceutical (603087.SH): Minghua Innovation reduced its holdings by a total of 5.9416 million shares
Gelonghui, Feb. 28, Gan Li Pharmaceutical (603087.SH) announced that during the period from February 5, 2024 to February 27, 2024, Minghua Innovation reduced its holdings by a total of 5.9416 million shares through centralized bidding, accounting for 1.00% of the company's total share capital. The holdings reduction plan has been completed.
Gan Lee Pharmaceuticals (603087.SH): No business partnerships with Eli Lilly and Novo Nordisk
Gelonghui, Feb. 28 | Gan Li Pharmaceutical (603087.SH) said on the investor interactive platform that the company currently has no business cooperation with Eli Lilly and Novo Nordisk.
Minghua Innovation, a shareholder of Ganli Pharmaceutical (603087.SH), reduced its holdings by 3.25 million shares by more than half
Ganli Pharmaceutical (603087.SH) issued an announcement. The company's shareholder Minghua Innovation will be held from February 5 to 20, 2024...
Guohai Securities: Domestic replacement+opening up the European and American markets, domestic insulin has entered a new stage
The Zhitong Finance App learned that Guohai Securities released a research report saying that with the steady increase in domestic insulin penetration rates and the gradual expansion of overseas markets, leading companies have fully benefited from the growth of the industry. Covered for the first time, giving the insulin industry a “recommended” rating. Focus on the company: Ganli Pharmaceutical (603087.SH) is a leading domestic third-generation insulin, and overseas expansion is imminent; Tonghua Dongbao (600867.SH) is a second-generation insulin leader, accelerating the development of the third-generation insulin market. ▍ Guohai Securities's main opinion is as follows: There are many diabetics in China, and foreign investment accounts for most of the market share. Released according to IDF
Ganli Pharmaceutical (603087.SH): The product under development, GZR18 injection is a GLP-1 weekly preparation for simultaneous clinical trials of hypoglycemic and weight loss indications
Gelonghui, Feb. 20: Ganli Pharmaceutical (603087.SH) said on the investor interactive platform that GZR4, an ultra-long-acting weekly insulin preparation, has completed the first phase II dose in China; the product under development, GZR18 injection, is a GLP-1 weekly preparation for simultaneous clinical trials of sugar reduction and weight loss indications. It was declared as a new drug. Among them, the phase II clinical trial of hypoglycemic indications is intended to be studied head-to-head with the original drug simeglutide. In addition, the company has accumulated experience in large-scale biopharmaceutical production and large-scale commerce over many years
Ganli Pharmaceutical (603087.SH) plans to launch a 7.13 million restricted stock incentive plan
Ganli Pharmaceutical (603087.SH) disclosed the 2024 Restricted Stock Incentive Plan (draft), which is intended for 90...
Gan & Lee Pharmaceuticals. (SHSE:603087) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
Gan & Lee Pharmaceuticals. (SHSE:603087) shares have had a horrible month, losing 30% after a relatively good period beforehand. To make matters worse, the recent drop has wiped out a year's worth
Gan & Lee Pharma's Insulin Product Gets Registration Approval in Bolivia
Gan & Lee Pharmaceuticals (SHA:603087) received approval from Bolivia's drug regulator to register its insulin aspart injection, Asparpen. The drug is used to control postprandial blood sugar and gluc
Ganli Pharmaceutical (603087.SH): Menton insulin injection obtained approval for drug registration in Bolivia
Gelonghui, January 25 | Ganli Pharmaceutical (603087.SH) announced that the company recently received an approval for the registration of insulin injections (cartridges) (approval number: II-87550/2023) from the Bolivian National Agency for Drugs and Health (Agencia Estatal de Medicamentos y Tecnologías en Salud, AGEMED). Menton insulin injection is a fast-acting insulin analogue. It works within 10 to 20 minutes after subcutaneous injection, and the maximum effect time is injected
Ganli Pharmaceutical (603087.SH): Net profit of 290 million yuan to 350 million yuan in 2023 is expected to turn a loss into a profit
Gelonghui, January 23丨Gan Li Pharmaceutical (603087.SH) announced the 2023 annual results pre-profit announcement. According to preliminary estimates by the finance department, it is estimated that net profit attributable to shareholders of listed companies in 2023 will be between RMB 290 million and RMB 35.00 million. Compared with the same period last year, it will turn a loss into a profit. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss is expected to be between $250,000 and $310.00 million in 2023. In 2023, the company's estimated net profit attributable to shareholders of listed companies and the previous year
Analysis
Price Target
No Data
